Asx Par News Today

Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Rating) insider Helen Fisher bought 10,204 shares of the stock in a transaction dated Thursday, May 18th. The shares were acquired at an average cost of A$0.98 ($0.65) per share, for a total transaction of A$10,020.33 ($6,680.22). Paradigm Biopharmaceuticals Price Performance The company has a debt-to-equity ratio of 0.53, […]

Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Rating) insider Paul Rennie bought 73,851 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were purchased at an average price of A$1.03 ($0.69) per share, with a total value of A$75,992.68 ($51,001.80). Paradigm Biopharmaceuticals Stock Performance The company has a quick ratio […]

“The achievements of FY21 are important in our journey as a company and help set a strong foundation for Paradigm to grow,” says interim chair and CEO.

Paradigm Biopharmaceuticals receives US FDA feedback on IND application for PPS in knee OA The company is on track to respond to questions from the US Food and Drug Administration around its Investigational New Drug application within 30 days. Paradigm is continuing Phase 3 study start-up preparation at sites in the US and Australia. Paradigm Biopharmaceuticals Ltd (ASX:PAR) (OTCMKTS:PBIGF) has received written feedback from the US Food and Drug Administration (FDA) regarding the i...

Paradigm Biopharmaceuticals Ltds (ASX:PAR) (OTCMKTS:PBIGF) Dr Jeannie Joughin tells Proactives Andrew Scott theyve received first revenue through...

Paradigm Biopharmaceuticals progresses IND application with US FDA for knee OA treatment The FDA was unable to provide all questions within the initial IND review period and has advised it will submit further questions to Paradigm within the next 30 days. Once the IND is Open the company may begin recruitment and screening of participants for the study. Paradigm Biopharmaceuticals Ltd (ASX:PAR) is making headway with its investigational new drug (IND) application for its proposed p...

Paradigm is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain...

Paradigm will be focused on Phase 3 trials of its drug Zilosul® during 2021, COO Jeannie Joughin told Proactive.